https://www.selleckchem.com/products/amg510.html
Introduction Despite recent advances in the treatment of adult acute myelogenous leukemia (AML), the overall outcome remains dismal especially in high-risk AML patients, including the elderly and the relapsed/refractory populations. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments.Areas covered The current paper reviews the clinical development of glasdegib, a selective inhibitor of the Hedgehog signaling pa
Aimer
Commentaire
Partagez
